NTC Srl and I-MED Pharma Inc announced today that I-DEFENSE^®, a long-lasting, lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the U.S.A. Food and Drug Administration. It is the first European NTC medical device product for ophthalmic use approved in the U.S.A.

NTC granted the license and commercialisation rights of its patented research and development product to Aspen for South Africa and other African countries, and has provided full technical and regulatory support to Aspen which has secured market authorisation for the product in South Africa.

NTC, international pharmaceutical company headquartered in Milan, Italy, and STADA, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (MENA) region, today announce a commercial ophthalmic partnership.

“Advanced scientific research and technology are the drivers of NTC’s innovation in care practices. While research is the soul of NTC, improving experience of care is our vocation which translates into new and specific therapeutic gestures: simple and intuitive, sustainable, and technically advanced for empowering the patient.” (Letter from the CEO)